New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:...
Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus”...
Law Offices of Howard G. Smith announces an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI ) investors concerning the Company’s...
New York, New York--(Newsfile Corp. - May 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:TLSI)...
TriSalus Life Sciences Inc. guided investors to $60-$62 million in 2026 revenue on March 5, then slashed that outlook to $54-$57 million months later
The Law Offices of Frank R. Cruz announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI ) on behalf of investors concerning...
New York, New York--(Newsfile Corp. - May 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:...
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed...
Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark,...
Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge...